LEO Pharma to Acquire Global Rights to Dersimelagon From Tanabe – Late‑Stage Oral Therapy for Rare Protoporphyrias Nears FDA Decision
LEO Pharma A/S announced that it has entered into an agreement with Tanabe Pharmaceutical to...
LEO Pharma
LEO Pharma Secures NMPA Approval for Enstilar Foam in China – First and Only Calcipotriol/Betamethasone Foam Formulation for Plaque Psoriasis Demonstrates Superior Efficacy vs. Ointment
LEO Pharma A/S has received marketing approval from China’s National Medical Products Administration (NMPA) for...
Er-Kim Secures Exclusive CEE Commercial Rights for LOQTORZI Anti-PD-1 Antibody from LEO Pharma
Er-Kim announced on April 14, 2026, that it has signed an exclusive commercialization agreement with...
LEO Pharma Submits NDA for Anzupgo in China for Chronic Hand Eczema
LEO Pharma announced on October 17, 2025, that it has submitted a New Drug Application...
Leo Pharma Secures First Greater Bay Area Prescription for Anzupgo, a Novel Topical JAK Inhibitor
Denmark-based dermatology specialist LEO Pharma A/S announced that the Greater Bay Area’s first prescription of...
Boehringer Ingelheim Licenses Spevigo to LEO Pharma for Global Dermatology Expansion
German pharmaceutical giant Boehringer Ingelheim (BI) this week announced a licensing agreement with Denmark-based dermatology...
Huapont Life Sciences Gains NMPA Approval for Generic Daivobet
China-based Huapont Life Sciences Co., Ltd (SHE: 002004) announced that it has received marketing approval...
Junshi Biosciences Licenses Toripalimab to LEO Pharma for EU and UK Markets
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced a licensing agreement...
Gilead Sciences and LEO Pharma Alliance Targets Inflammatory Diseases
US-based major Gilead Sciences Inc. (NASDAQ: GILD) has formed a strategic alliance with Denmark-based dermatology...
LEO Pharma’s Enstilar Outperforms Daivobet in Phase III Psoriasis Trial in China
Denmark-based dermatology specialist LEO Pharma A/S has announced positive outcomes for its drug candidate Enstilar...
LEO Pharma Initiates Phase III Clinical Trial for Delgocitinib in China
Denmark-based LEO Pharma A/S has announced the commencement of a China Phase III clinical study...